Literature DB >> 8900307

Comparison of adenovirus gene transfer to vascular endothelial cells in cell culture, organ culture, and in vivo.

A F Merrick1, L D Shewring, G J Sawyer, K T Gustafsson, J W Fabre.   

Abstract

A replication-defective adenovirus 5 vector carrying the beta-galactosidase reporter gene was tested for its efficiency for gene delivery to vascular endothelial cells in various situations. Both porcine and human primary vascular endothelial cell cultures were very efficiently infected (>90%) at adenovirus concentrations of 10(10) pfu/ml or higher. Cultured rat fibroblasts and keratinocytes were even more readily infected, with >90% infection with adenovirus titers of 10(8) pfu/ml or higher. However, nondividing vascular endothelium in situ was very poorly transduced. Pieces of aorta from adult pigs, sheep, rabbit and rat, and pieces of human umbilical artery and vein were studied in organ culture. These showed only occasional positive vascular endothelial cells when exposed to the adenovirus vector at concentrations up to 5x10(11) pfu/ml. Kidney perfusion studies in rats and pigs gave similar results. The only exception to the above findings was in very young (3-4 day old) piglets, which showed excellent (>90%) infection of vascular endothelium with the adenovirus vector at titers of 10(10) pfu/ml. Our data suggest that adenovirus vectors will not be of value for gene delivery to uninjured vascular endothelium in situ, and are therefore unsuited for ex vivo genetic manipulation of vascular endothelium in organs for transplantation.

Entities:  

Mesh:

Year:  1996        PMID: 8900307     DOI: 10.1097/00007890-199610270-00011

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  8 in total

Review 1.  Targeting gene therapy vectors to the vascular endothelium.

Authors:  Lorraine M Work; Stuart A Nicklin; Andrew H Baker
Journal:  Curr Atheroscler Rep       Date:  2003-05       Impact factor: 5.113

2.  Intratumoral injection of Ad-ISF35 (Chimeric CD154) breaks tolerance and induces lymphoma tumor regression.

Authors:  Mauricio Urquiza; Johanna Melo-Cardenas; Robier Aguillon; Thomas J Kipps; Januario E Castro
Journal:  Hum Gene Ther       Date:  2015-01       Impact factor: 5.695

3.  Efficient nanoparticle mediated sustained RNA interference in human primary endothelial cells.

Authors:  Anindita Mukerjee; Jwalitha Shankardas; Amalendu P Ranjan; Jamboor K Vishwanatha
Journal:  Nanotechnology       Date:  2011-10-11       Impact factor: 3.874

4.  A novel Flk1-TVA transgenic mouse model for gene delivery to angiogenic vasculature.

Authors:  Virginie S Vervoort; Mark Lu; Fatima Valencia; Jacqueline Lesperance; Georg Breier; Robert Oshima; Elena B Pasquale
Journal:  Transgenic Res       Date:  2007-11-20       Impact factor: 2.788

Review 5.  Advances and future challenges in adenoviral vector pharmacology and targeting.

Authors:  Reeti Khare; Christopher Y Chen; Eric A Weaver; Michael A Barry
Journal:  Curr Gene Ther       Date:  2011-08       Impact factor: 4.391

Review 6.  Human Organ Culture: Updating the Approach to Bridge the Gap from In Vitro to In Vivo in Inflammation, Cancer, and Stem Cell Biology.

Authors:  Rafia S Al-Lamki; John R Bradley; Jordan S Pober
Journal:  Front Med (Lausanne)       Date:  2017-09-11

7.  SR-A and SREC-I are Kupffer and endothelial cell receptors for helper-dependent adenoviral vectors.

Authors:  Pasquale Piccolo; Francesco Vetrini; Pratibha Mithbaokar; Nathan C Grove; Terry Bertin; Donna Palmer; Philip Ng; Nicola Brunetti-Pierri
Journal:  Mol Ther       Date:  2013-01-29       Impact factor: 11.454

8.  Assessment of a novel, capsid-modified adenovirus with an improved vascular gene transfer profile.

Authors:  Katie M White; Raul Alba; Alan L Parker; Audrey F Wright; Angela C Bradshaw; Christian Delles; Robert A McDonald; Andrew H Baker
Journal:  J Cardiothorac Surg       Date:  2013-08-09       Impact factor: 1.637

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.